Marinomed Biotech AG

Marinomed Biotech AG begins contract negotiations for the sale of the Carragelose portfolio

Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share

Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights

Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights

Marinomed Biotech AG: Court opens restructuring proceedings without self-administration

Marinomed Biotech AG applies for court restructuring proceedings without self-administration